Elexacaftor|2216712-66-0|-陌孚医药/Medlife

您当前的位置：

Elexacaftor

目录号: PL13129 纯度: ≥99%

CAS No. :2216712-66-0

商品编号	规格	价格	会员价
PL13129-1mg	1mg	¥1768.00	请登录
PL13129-5mg	5mg	¥6107.00	请登录
PL13129-10mg	10mg	¥9804.00	请登录
PL13129-50mg	50mg	询价	询价
PL13129-100mg	100mg	询价	询价
PL13129-10mM*1mLinDMSO	10mM*1mLinDMSO	¥8036.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Elexacaftor
英文名称	Elexacaftor
英文别名	Elexacaftor;Elexacaftor (USAN);Elexacaftor [USAN];(S)-N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-(2,2,4-trimethylpyrrolidin-1-yl)nicotinamide;RRN67GMB0V;GTPL10552;WHO 11180;s8851;DB15444;Compound 1 [WO2018107100A1];D11507;N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-t;VX-445
Cas No.	2216712-66-0
分子式	C₂₆H₃₄F₃N₇O₄S
分子量	597.65
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Elexacaftor (VX-445, Compound 1) 是一种囊性纤维化跨膜电导调节因子 (CFTR) 校正剂。Elexacaftor (VX-445, Compound 1) 促进CFTR的加工和转运，增加细胞表面CFTR的数量。

生物活性

Elexacaftor (VX-445, Compound 1) is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR). Elexacaftor (VX-445, Compound 1) facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface.

性状

Solid

IC50 & Target[1][2]

CFTR.

体外研究(In Vitro)

Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function. Elexacaftor (VX-445) has the potential to treat cystic fibrosis. VX-445-Tezacaftor-VX-770 significantly improves Phe508del CFTR protein processing, trafficking, and chloride transport to a greater extent than any two of these agents in dual combination. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Alexander Russell Abela, et al. MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR , PHARMACEUTICAL COMPOSITIONS , METHODS OF TREATMENT , AND PROCESS FOR MAKING THE MODULATOR. US 20180162839 A1.
[2]. Keating D, et al. VX-445-Tezacaftor-VX-770 in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1612-1620.

溶解度数据	In Vitro: DMSO : 125 mg/mL (209.15 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation